Clarity Pharmaceuticals (ASX:CU6) - Aandelenkoers, Nieuws & Analyse

CU6 Overzicht aandelen

Clarity Pharmaceuticals Ltd, een radiofarmaceutisch bedrijf in een klinische fase, houdt zich bezig met onderzoek en ontwikkeling en radiofarmaceutische producten in een klinische fase in Australië en de Verenigde Staten. Meer informatie

CU6 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Analisten zijn het erover eens dat de aandelenkoers met 56.6% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Clarity Pharmaceuticals Ltd Concurrenten

Neuren Pharmaceuticals

ASX:NEU

AU$1.6b

Arovella Therapeutics

ASX:ALA

AU$200.5m

Mayne Pharma Group

ASX:MYX

AU$363.5m

Botanix Pharmaceuticals

ASX:BOT

AU$581.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clarity Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	AU$5.68
52 Week Hoogtepunt	AU$8.98
52 Week Laag	AU$1.26
Bèta	1.68
11 maand verandering	-15.10%
3 maanden verandering	-15.48%
1 Jaar Verandering	342.02%
33 jaar verandering	552.87%
5 jaar verandering	n/a
Verandering sinds IPO	278.67%

Recent nieuws en updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13

Rendement voor aandeelhouders

	CU6	AU Pharmaceuticals	AU Markt
7D	-20.4%	-16.4%	0.9%
1Y	342.0%	32.2%	18.4%

Rendement versus industrie: CU6 overtrof de Australian Pharmaceuticals industrie, die het afgelopen jaar een rendement 32.2 % opleverde.

Rendement versus markt: CU6 overtrof de Australian markt, die het afgelopen jaar een rendement opleverde van 18.4 %.

Prijsvolatiliteit

Is CU6's price volatile compared to industry and market?
CU6 volatility
CU6 Average Weekly Movement	9.3%
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.3%

Stabiele aandelenkoers: CU6 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van CU6 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	50	Michelle Parker	www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd, een radiofarmaceutisch bedrijf in een klinische fase, houdt zich bezig met onderzoek en ontwikkeling van radiofarmaceutische producten in Australië en de Verenigde Staten. De producten van het bedrijf omvatten SARTATE, een gericht theranostisch radiofarmaceuticum dat wordt gebruikt voor de diagnose, stadiëring en behandeling van kankers die somatostatinereceptor 2 tot expressie brengen; de ontwikkeling van SAR-bombesin, een theranostisch radiofarmaceuticum voor pan-kanker dat wordt gebruikt voor de diagnose, stadiëring en behandeling van kankers die gastrine releasing peptide receptor tot expressie brengen; SAR-bisPSMA, een theranostisch radiofarmaceuticum dat wordt gebruikt voor de diagnose, stadiëring en behandeling van kankers die prostaat-specifiek membraanantigeen tot expressie brengen. Het ontwikkelt theranostische therapie- en beeldvormingsproducten voor de behandeling van kanker bij kinderen en volwassenen.

Clarity Pharmaceuticals Ltd Samenvatting

Hoe verhouden de winst en inkomsten van Clarity Pharmaceuticals zich tot de beurswaarde?
CU6 fundamentele statistieken
Marktkapitalisatie	AU$1.82b
Inkomsten(TTM)	-AU$42.32m
Inkomsten(TTM)	AU$11.51m

158.1x

P/S-verhouding

-43.0x

Koers/Winstverhouding

Is CU6 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CU6 resultatenrekening (TTM)
Inkomsten	AU$11.51m
Kosten van inkomsten	AU$0
Brutowinst	AU$11.51m
Overige uitgaven	AU$53.83m
Inkomsten	-AU$42.32m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.13
Brutomarge	100.00%
Nettowinstmarge	-367.83%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CU6 op de lange termijn?

Bekijk historische prestaties en vergelijking

CU6 Overzicht aandelen

Beloningen

Risicoanalyse

Clarity Pharmaceuticals Ltd Concurrenten

ASX:NEU

AU$1.6b

ASX:ALA

AU$200.5m

ASX:MYX

AU$363.5m

ASX:BOT

AU$581.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer

MD, CEO & Executive Director exercised options to buy AU$8.3m worth of stock.

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 20, 2024

Now 21% overvalued after recent price rise

Recent updates

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer

MD, CEO & Executive Director exercised options to buy AU$8.3m worth of stock.

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 20, 2024

Now 21% overvalued after recent price rise

Clarity Pharmaceuticals Confirms the Appointment of Ms. Michelle Parker to Its Board, Effective September 20, 2024

Clarity Pharmaceuticals Ltd Receives FDA Fast Track Designation for 64Cu-Sar-Bispsma

MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock.

No longer forecast to breakeven

Executive Chairman exercised options to buy AU$3.4m worth of stock.

No longer forecast to breakeven

No longer forecast to breakeven

Price target increased by 14% to AU$3.87

New minor risk - Shareholder dilution

Clarity Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Clarity Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Non-Executive Director exercised options to buy AU$1.1m worth of stock.

Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial

Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range

New major risk - Financial position

Price target increased by 13% to AU$2.48

Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA

Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level

Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE

Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial

Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer (Mcrpc)

Price target increased by 8.5% to AU$1.82

New major risk - Revenue and earnings growth

Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure

Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin

New minor risk - Profitability

MD, CEO & Executive Director exercised options to buy AU$493k worth of stock.

Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer

Consensus EPS estimates fall by 13%

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase by 261%

MD, CEO & Executive Director exercised options to buy AU$243k worth of stock.

Clarity Pharmaceuticals Ltd Announces Its Phase II Diagnostic 64 Cu Sartate Trial (Disco NCT04438304)

Clarity Pharmaceuticals Announces PROPELLER Trial Results - SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer

Clarity Pharmaceuticals Ltd Announces Diagnostic Prostate Cancer Trial Reaches Recruitment Target

Clarity Pharmaceuticals Ltd Announces Board Changes

Clarity Pharmaceuticals Ltd Announces Positive Topline Results from SAR-bisPSMA Diagnostic Trial

Price target increased to AU$1.54

Clarity Pharmaceuticals Announces IND Approval from the FDA for Theranostic Sar-Bombesin Trial in Prostate Cancer

Less than half of directors are independent

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Phase II BOP Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces First Patient Treated in Therapeutic Prostate Cancer Trial

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 24, 2022

Consensus forecasts updated

Clarity Pharmaceuticals Ltd Successfully Imaged Its First Participants in the Diagnostic 64 CU SAR-Bombesin Trial (Bop) for Patients with PSMA-Negative Prostate Cancer in Australia

Clarity Pharmaceuticals Appoints Jeffrey Norenberg as Chief Scientific Officer